(Reuters) – Swiss dental implants maker Straumann on Wednesday raised its 2022 organic sales growth outlook, citing post-pandemic recovery momentum.
The company, which specialises in tooth replacement and orthodontic solutions, expects its revenue to grow in the mid-teens percentage range organically, against its earlier forecast for low-double-digit percentage growth.
Straumann’s third-quarter organic sales came in at 551 million Swiss francs ($552 million), up 12% compared to last year.
“We were able to deliver a very good quarter despite the ongoing macro-economic uncertainties,” Chief Executive Guillaume Daniellot said in a statement.
Dental care providers, who last year benefited from increased demand for specialty treatments as practices reopened after the easing of COVID-19-related lockdowns, have now also been reassured by fewer lockdowns in core market China.
The country represents more than half of Straumann’s overall business in the Asia-Pacific region, where sales grew by almost 9% organically in the third quarter.
Straumann confirmed its full-year guidance for core earnings before interest and taxes (EBIT) margin of around 26%, including significant growth investments.
($1 = 0.9985 Swiss francs)
(Reporting by Bartosz Dabrowski in Gdansk; editing by Milla Nissi)
